

23 Jan 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: GSK's R&D head departs; Bayer's pharma R&D chief prioritizes assets; new US launches in atopic dermatitis; is Abivax an M&A target; and China's gene therapy developers rush to the clinic.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 21 January 2022, including: [GlaxoSmithKline plc's](#) R&D head departs; [Bayer AG's](#) pharma R&D chief prioritizes assets; new US launches in atopic dermatitis; is [Abivax S.A.](#) an M&A target; and China's gene therapy developers rush to clinic.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Hal Barron To Depart GSK To Head Up New Biotech](#)" - Scrip, 19 Jan, 2022.)

(Also see "[Bayer Pharma R&D Head Tackles Challenge Of Prioritizing Promising Assets](#)" - Scrip, 14 Jan, 2022.)

(Also see "[Pfizer And AbbVie JAKs Finally Join Dupixent In US Atopic Dermatitis Space](#)" - Scrip, 17 Jan, 2022.)

(Also see "[France's Abivax Looks A Likely M&A Target](#)" - Scrip, 14 Jan, 2022.)

(Also see "[*China Gene Therapy Developers Rush To Clinic In 'Winner Takes All' Battle*](#)" - Scrip, 18 Jan, 2022.)

[*Click here to explore this interactive content online*](#) ✎